Issue 13 - Mar. 27, 2020
Issue 12 - Mar. 20, 2020
Issue 11 - Mar. 13, 2020
  • Guest Editorial

    COVID-19 and the cancer patient: A call to action for balancing cancer care and viral risk

    As COVID-19 has now officially been declared a source of the pandemic, with increasing incidence across the nation, it is without question that the needs of patients with particular vulnerabilities should garner particular attention.

  • Pandemic: Bracing for coronavirus surge

    The COVID-19 pandemic will affect every aspect of cancer care and cancer research.

  • Conversation with The Cancer Letter

    Is your cancer center ready for COVID-19?

    The Cancer Letter spoke with leaders from the Fred Hutchinson Cancer Research Center, MD Anderson Cancer Center, University of California, Los Angeles, and Robert H. Lurie Comprehensive Cancer Center of Northwestern University to gauge the impact of coronavirus.

  • Conversation with The Cancer Letter

    What to expect: Oncology’s response to coronavirus in Italy

    “It’s like being in a war”

     To get a sense of how COVID-19 will affect oncology in the U.S., The Cancer Letter called Giuseppe Curigliano, associate professor of Medical Oncology at University of Milano and the head of the Division of Early Drug Development at European Institute of Oncology, Italy, who is based in the Lombardy region—the epicenter of the outbreak.

  • TCCL Logo

  • Trials & Tribulations

    A conversation about COVID-19: reflecting on first cases in Kansas

    The following is a transcript from a weekly Facebook Live program, where Roy Jensen, director of The University of Kansas Cancer Center and Kansas Masonic Cancer Research Institute, interviews cancer researchers, clinicians, and patients.

  • Clinical Roundup

    • FDA encourages inclusion of older adult patients in cancer clinical trials
    • Phase III GY004 for Cediranib and Lynparza doesn’t meet PFS endpoint in ovarian cancer indication
    • Copper IUDs less likely to contribute to cervical cancer than hormonal IUDs
  • Drugs & Targets

    • FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma
    • FDA accepts BLA for biosimilar MYL-1402O in cancer indications
    • FDA grants Breakthrough Therapy Designation for JNJ-6372 in NSCLC indication
    • Thermo Fisher Scientific collaborates with Janssen to co-develop companion diagnostic for cancer
    • European Commission approves Venclyxto in CLL indication